Actinium Pharmaceuticals, Inc. (delaware) · AMEX:ATNM
Actinium Pharmaceuticals, Inc. (delaware) — Actinium Pharmaceuticals — Investor Presentation (September 2014)
25 slides from Actinium Pharmaceuticals, Inc. (delaware)'s investor presentation, Sep 25, 2014
Slide 1: Actinium Pharmaceuticals Company Presentation
Actinium Pharmaceuticals, Inc. 4j N September/October 2014 Company Presentation Trading Symbol: ATNM
Slide 2: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement Disclaimer ‘The contents of this presentation and the information which you ate given at the time of these slides and the presentation have aot been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Re
Slide 3: Company Description
Company Description A public biotechnology company using world class science to develop and commercialize antibody directed radioisotopes to target unmet medical needs in cancer. ‘Actinium Pharmaceuticals
Slide 4: Company Overview
Company Overview Prior clinical data for lomab-B and Actimab-A support pivotal/phase TI development respectively Potential as breakthrough therapy, significant unmet medical need and strong KOL support imply successful market penetration for both Tomab-B and Actimab-A APIT platform poised to deliver
Slide 5: Core Team & Advisors
Sandesh Seth, MS, MBA Executive Chairman, Kaushik J. Dave, PhD, MBA. President and CEO Dragan Cicic, MD, MBA Chief Medical Officer Richard Steinhart BBA, MBA Director Sergio Traversa, PharmD, MBA Director David Nicholson, PhD Director ‘Actinium Pharmaceuticals Core Team & Advisors cam 20+ years expe
Slide 6: Advisory Boards
Advisory Boards Bone Marrow Transplant; lomab-B (8) Affiliation Fred Hutchinson Cancer Research Center Memorial Sloan Kettering Cancer Center MD Anderson Cancer Center Case Western Reserve University Baylor Sammons Cancer Center University of Colorado ‘Actinium Pharmaceuticals Member John Pagel, MD,
Slide 7: Antibody Approaches Targeting Cancer Cells
Antibody Approaches Targeting Cancer Ce Cancer Treatment Options Radiation Monoclonal Antibodies (mAbs) ‘Treatment % 50% @ External radiation majority treatment <10% Always a pharmaccutical Ph: seal ¢ Internal radiation has mostly no IP @ Strong IP protection armace ute: <3% ¢ Commoditized ~30% % Mo
Slide 8: ATNM's Product Pipeline
ATNM’s Product Pipeline Development Status Tomab-B HSCT! (Bone Marrow) Bismab-A? AML Actimab-A (6d) AML ——_kzx— > sd. — single dose f£.d.— fractionated dose (2) Actimab-A (Ed) AML > Third Program Not Disclosed ==> Actimab-C Colon Cancer i. Actimab-P Prostate Cancer ==> Actimab-Br Breast Cancer —S=>
Slide 9: Market Positioning for Iomab-B, Actimab-A
Market Positioning for lomab-B, Actimab-A ATNM products target both treatment stages for AML patients over 55 years of age Diagnosis Treatment Response Treatments MM Corrent Treatments HB ATNM Pipetine Drugs 1) Positive Response xX Hl Negative Response » ‘Actinium Pharmaceuticals
Slide 10: Iomab-B Overview
Iomab-B Overview ¢ Breakthrough therapy potential for BMT conditioning especially for elderly, very sick patients with few curative treatment options — Initial intended indication is relapsed, refractory AML patients over 55 years old + Compelling clinical data from proof of concept trial in elderly
Slide 11: Iomab-B Treatment
Iomab-B Treatment Potentially faster pathway to a bone marrow transplant with fewer side effects 28-42 Days 4-Days €X " ‘Actinium Pharmaceuticals
Slide 12: Iomab-B Phase I/II Results
Iomab-B Phase I/II Results Compelling clinical results enable pivotal Phase II trial * — Non-relapse mortality (NRM): = Day 100: 10% — Overall: 20% (NRM_ = 46% in comparable patients with myeloablative conditioning) * — Transplant related mortality: 14% (same as reduced intensity conditioning) ¢ Com
Slide 13: Iomab-B Pivotal Phase III Trial Design
Iomab-B Pivotal Phase III Trial Design + A successful End of Phase II meeting was held with the FDA and agreements were reached on the following Phase III Trial Design: — Initial indication: bone marrow conditioning in relapsed and refractory AML — Patients age: 55+ — Study size: 150 subjects; 75 pe
Slide 14: Bone Marrow Transplant Centers
Bone Marrow Transplant Centers Ten centers perform thirty percent of AML transplants; HSCT fastest growing hospital procedure in the US A total of 2,748 AML patients received allogeneic transplants in 2012 MD Anderson Dana Farber City of Hope ‘Washington Univ. Fred Hutchinson H Lee Moffitt Johns Hop
Slide 15: Iomab-B Development Plan
Iomab-B Development Plan Currently no approved treatments for Iomab-B targeted patients implies blockbuster potential WW Mkt. indication 2014-2015 201620172018 2019 potential Approval Aewe Myo Leven i sm Approval Acute Lymphoblastic Leukemia Non-Hodgkins Lymphoma Lass Total $ 4,098 Phase I and Phase
Slide 16: Iomab-B A New Treatment Paradigm
Iomab-B A New Treatment Paradigm v Provides treatment alternative to patients with no options v Significantly expands patient population eligible for BMT v Provides potentially a faster way of performing BMT with fewer side effects v¥ Minimizes transplant related mortality Y Significantly increases
Slide 17: Bismab-A to Actimab-A
Bismab-A E> Actimab-A Second generation Actimab-A 500x more potent than Bismab-A 1 Generation 2°¢ Generation Bismab-A Profile Actimab-A Advantages Target: ¢ AML @ AML Effectiveness: ¢ Proof of concept in humans + 500x mote potent than Bismab-A Clinical Stage: ¢ Promising results in Phase IT ¢ Curren
Slide 18: Bismab-A's Proof of Concept
Bismab-A’s Proof of Concept Bismab-A experience implies potentially lower risk Actimab-A trial T ‘Median survival 4x greater than historical data for untreated patients* ig i a 100% + Elighatis AML patients; newly wove 05 mCi eg diagnosed and relapsed/reftactory os 075 mCi/kg vo BL mCi/ky 1.25 mCi/k
Slide 19: Phase I Trial of Actimab-A
Phase I Trial of Actimab-A Pharmacologic effects in line with Bismab-A 150% 125% 100% 15% 50% 25% ¢ — First-in-man, dose-escalating study at Memorial Sloan Kettering Cancer Center + No significant toxicities; bone marrow myelosuppression as expected. ¢ 53% (8/15) had blast reductions of = 50% ¢ Acti
Slide 20: Actimab-A Clinical Trial Update
Actimab-A Clinical Trial Update ¢ Phase I/II clinical trial ongoing at world-class treatment centers - Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, Fred Hutchinson Cancer Research Center, University of Pennsylvania Health Center, MD Anderson Cancer Center, Baylor Sammons Cancer Ce
Slide 21: ATNM's Proprietary Technology Platform
ATNM’s Proprietary Technology Platform APIT Technology Key Highlights Antibody (targeting agent) ¢ Proprietary strategy for Actimab-A encompasses patents for core aspects of deug preparation, production, composition and treatment using alpha radiation. + 35 Patents issued and pending, United States
Slide 22: Market Potential of Product Pipeline
2 38 ae 58 1 BMT (Iomab-B) ‘Actinium Phat Bone Marrow Transplant (BMT) Acute Myeloid Leukemia (AML) Glioblastoma Multiforme (GBM) Prostate Cancer (metastatic) Metastatic Colorectal Cancer ‘Target mariet includes USA, EU and Japan Market Potential of Product Pipeline 2 48,000 41,600 26,500 591,000 53
Slide 23: Near-term Value Drivers
Neat-term Value Drivers Multiple milestones in next 12-18 months ¢ Tomab-B v Complete Phase III Protocol v Start CGMP mAb mfg v Start drug mfg cGMP process — Complete cGMP mAb mfg — Complete Drug mfg cGMP — Submit Phase IIT IND — Start Phase IIT ¢ Actimab-A — Complete Phase I trial — Complete mfg. i
Slide 24: Company Overview
Company Overview v Prior clinical data for Iomab-B and Actimab-A support pivotal/phase TI development respectively v Potential as breakthrough therapy implies successful market penettation for both Iomab-B and Actimab-A vy APIT platform poised to deliver multiple cancer drugs with blockbuster potent
Slide 25: Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. / N September/ October 2014 Company Presentation Trading Symbol: ATNM
Actinium Pharmaceuticals — Investor Presentation (September 2014) on 6ix